Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Endogenous digitalis: pathophysiologic roles and therapeutic applications Bagrov AY; Shapiro JINat Clin Pract Nephrol 2008[Jul]; 4 (7): 378-92Endogenous digitalis-like factors, also called cardiotonic steroids, have been thought for nearly half a century to have important roles in health and disease. The endogenous cardiotonic steroids ouabain and marinobufagenin have been identified in humans, and an effector mechanism has been delineated by which these hormones signal through the sodium/potassium-transporting ATPase. These findings have increased interest in this field substantially. Although cardiotonic steroids were first considered important in the regulation of renal sodium transport and arterial pressure, subsequent work has implicated these hormones in the control of cell growth, apoptosis and fibrosis, among other processes. This Review focuses on the role of endogenous cardiotonic steroids in the pathophysiology of essential hypertension, congestive heart failure, end-stage renal disease and pre-eclampsia. We also discuss potential therapeutic strategies that have emerged as a result of the increased understanding of the regulation and actions of cardiotonic steroids.|*Cardiovascular Diseases/drug therapy/metabolism/physiopathology[MESH]|*Kidney Diseases/drug therapy/metabolism/physiopathology[MESH]|Animals[MESH]|Blood Pressure/physiology[MESH]|Digitalis Glycosides/*metabolism/*therapeutic use[MESH]|Enzyme Inhibitors/*metabolism/*therapeutic use[MESH]|Glomerular Filtration Rate/physiology[MESH]|Humans[MESH]|Kidney/drug effects/metabolism[MESH]|Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors/metabolism[MESH]|Treatment Outcome[MESH] |
